Fig. 8
From: Single protein encapsulated SN38 for tumor-targeting treatment
Mean TV and % BW changes vs treatment time, tumor weights for SPESN38-8 and doxorubicin for SPESN38-8. A Mean tumor volume vs treatment time for 4 male and 4 female mice. Mice # for each group, control (n = 8), DOX (n = 8), and SPESN38-8, IV (n = 8). On Day 6, DOX, TGI, 26.9%, significantly lower than control group (**, p = 0.0039), SPESN38-8, TGI, 68.5%, very significantly lower than control group (***, p < 0.0001). On Day 9, DOX, TGI, 25.3%, very significantly lower than control group (***, p < 0.0001), SPESN38-8, TGI, 86.2%, very significantly lower than control group (***, p < 0.0001), SPESN38-8, very significantly reduced tumor volume, compared to DOX group (***, p < 0.0001). On Day 21, SPESN38-8 treatment group had three mice free of tumors; B % BW change vs treatment time for all mice. DOX group at 5 mg/kg (qwk × 2) shown severe and unacceptable toxicity, all mice have to be euthanized on Day 9. But SPESN38-8 at 33 mg/kg (qwk × 3) group did not display any BW loss; C Comparison of the average tumor weights at their ending points